Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.
During the most recent quarter, 3K shares were bought, and 3K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.